Browse the evidence

The nanocomplexes showed markedly delayed release of semaglutide, with only 19% drug release over 7 days.

The delayed release may improve the effectiveness of semaglutide in clinical settings.

In 2022, 1 in 8 people in the world were living with obesity.

Practitioners should be aware of the significant prevalence of obesity.

Key chemobiological mechanisms implicated in obesity include dysregulated leptin-ghrelin signaling, chronic low-grade inflammation, and altered adipokine profiles.

Understanding these mechanisms can help in developing targeted interventions for obesity.

Receptor activity-modifying proteins (RAMPs) are involved in the incidence of obesity and diabetes mellitus.

Understanding the role of RAMPs may help in developing targeted therapies for obesity and diabetes.

Dysregulation of pathways involving class B1 receptors can lead to obesity and diabetes mellitus.

Addressing dysregulation in these pathways may be crucial for obesity and diabetes management.

More research is required to fully understand the contribution of RAMPs to obesity and diabetes.

Future studies should focus on RAMPs to clarify their roles in obesity and diabetes.

Obesity was recognized as a disease by the German Bundestag on July 3, 2020.

This recognition may influence treatment protocols and funding for obesity management.

There is a lack of studies comparing adverse events across different populations for glucagon-like peptide-1 receptor agonists.

Further research is needed to assess the safety of glucagon-like peptide-1 receptor agonists across diverse populations.

There is an urgent need for fundamental research to understand the mechanisms of metabolic disorders and cardiovascular disease.

Invest in research to better understand and treat metabolic and cardiovascular diseases.

Advances in understanding molecular causes of rare genetic obesities have led to therapies targeting appetite regulation.

Practitioners should consider new therapies targeting appetite regulation for patients with rare genetic obesities.

Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and bile acid receptors including the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5).

Practitioners should stay informed about these novel molecular targets for potential future therapies in obesity management.

Further research is needed to assess the long-term safety of Tirzepatide, particularly regarding cardiovascular outcomes.

Practitioners should be aware of the need for ongoing evaluation of Tirzepatide's long-term safety profile.

Interdisciplinary collaboration and communication between anaesthetists, surgeons, general practitioners, and endocrinologists are required to further investigate and establish preoperative guidelines for safe GLP-1 agonist use.

Healthcare teams should work together to create and follow guidelines for managing patients on GLP-1 agonists in surgical settings.

GLP-1 receptor agonists can exist stably in patients for a long time, overcoming the short half-life of natural GLP-1.

Practitioners can expect longer-lasting effects from GLP-1 receptor agonists compared to natural GLP-1.

Collagen and free amino acid ingestion did not significantly increase myofibrillar protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance muscle protein synthesis in healthy individuals post-exercise.

Collagen and free amino acid ingestion did not significantly increase muscle connective protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance connective tissue protein synthesis in healthy individuals post-exercise.

62% of protein supplement users were male.

Practitioners should note the gender distribution in protein supplement use.

42% of protein supplement users were aged 25–34.

Targeted educational initiatives can be focused on this age group.

Up to half of patients with diabetes mellitus are undiagnosed when referred for elective surgery.

Healthcare providers should consider screening for diabetes in patients scheduled for elective surgery.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the food supply increased much more than population needs.

This suggests that dietary guidelines may need to be adjusted to account for excess energy availability.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

GLP-1RAs can induce gastric food retention, increasing the risk for pulmonary aspiration during anesthesia.

Clinicians should consider the risk of pulmonary aspiration when using GLP-1RAs in patients undergoing anesthesia.

Management of GLP-1RA adverse events lacks evidence-based support.

Healthcare providers should be cautious in applying management strategies for GLP-1RA adverse events due to the lack of evidence.